Bridgefront Capital’s Vir Biotechnology VIR Stock Holding History

Bridgefront Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,427	Closed	-$93.4K	–	767
2026 Q1	$93.4K	Buy	+10,427	New	+$83.1K	0.02%	501
2025 Q2	–	Sell	-28,205	Closed	-$183K	–	868
2025 Q1	$183K	Buy	+28,205	New	+$251K	0.05%	533
2024 Q3	–	Sell	-15,751	Closed	-$140K	–	729
2024 Q2	$140K	Buy	+15,751	New	+$151K	0.06%	437

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bridgefront Capital's VIR Position: Q2 2026 in Review

Bridgefront Capital sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 10,427 shares — an estimated $93.4K sold.

Bridgefront Capital first reported a position in VIR in Q2 2024 and held it in 3 quarters. The position peaked at $183K in Q1 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Bridgefront Capital reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
Bridgefront Capital sold 10,427 Vir Biotechnology shares in Q2 2026, an estimated $93.4K.
Bridgefront Capital first reported a position in Vir Biotechnology in Q2 2024 and held it in 3 quarters.
Bridgefront Capital's Vir Biotechnology position peaked at $183K in Q1 2025.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.